|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: JMY |
Gene summary for JMY |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | JMY | Gene ID | 133746 |
| Gene name | junction mediating and regulatory protein, p53 cofactor | |
| Gene Alias | WHAMM2 | |
| Cytomap | 5q14.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8N9B5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 133746 | JMY | HTA11_347_2000001011 | Human | Colorectum | AD | 3.60e-04 | 1.67e-01 | -0.1954 |
| 133746 | JMY | HTA11_1391_2000001011 | Human | Colorectum | AD | 4.63e-03 | 2.76e-01 | -0.059 |
| 133746 | JMY | HTA11_866_3004761011 | Human | Colorectum | AD | 1.25e-02 | 1.17e-01 | 0.096 |
| 133746 | JMY | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.33e-02 | 2.78e-01 | 0.0588 |
| 133746 | JMY | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 3.44e-02 | 6.26e-01 | 0.3487 |
| 133746 | JMY | HTA11_99999965104_69814 | Human | Colorectum | MSS | 4.07e-08 | 5.98e-01 | 0.281 |
| 133746 | JMY | HCC1_Meng | Human | Liver | HCC | 2.19e-11 | -3.21e-02 | 0.0246 |
| 133746 | JMY | HCC2 | Human | Liver | HCC | 3.71e-08 | 2.95e+00 | 0.5341 |
| 133746 | JMY | Pt13.b | Human | Liver | HCC | 1.89e-06 | 1.03e-01 | 0.0251 |
| 133746 | JMY | S015 | Human | Liver | HCC | 7.39e-06 | 3.54e-01 | 0.2375 |
| 133746 | JMY | S016 | Human | Liver | HCC | 1.21e-07 | 3.07e-01 | 0.2243 |
| 133746 | JMY | S028 | Human | Liver | HCC | 1.85e-03 | 2.77e-01 | 0.2503 |
| 133746 | JMY | S029 | Human | Liver | HCC | 8.07e-10 | 5.41e-01 | 0.2581 |
| 133746 | JMY | GSM5252137_BPH556PrGA2_Fcol | Human | Prostate | BPH | 1.45e-02 | 2.13e-01 | -0.23 |
| 133746 | JMY | 048752_1579-all-cells | Human | Prostate | BPH | 1.19e-16 | 4.64e-01 | 0.1008 |
| 133746 | JMY | 052095_1628-all-cells | Human | Prostate | BPH | 1.04e-06 | 2.52e-01 | 0.1032 |
| 133746 | JMY | 052097_1595-all-cells | Human | Prostate | BPH | 3.64e-21 | 5.17e-01 | 0.0972 |
| 133746 | JMY | 052099_1652-all-cells | Human | Prostate | BPH | 6.92e-10 | 3.26e-01 | 0.1038 |
| 133746 | JMY | Dong_P1 | Human | Prostate | Tumor | 7.85e-09 | 4.42e-02 | 0.035 |
| 133746 | JMY | Dong_P3 | Human | Prostate | Tumor | 3.58e-06 | 7.81e-02 | 0.0278 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0007015 | Colorectum | AD | actin filament organization | 167/3918 | 442/18723 | 1.65e-16 | 7.94e-14 | 167 |
| GO:0032535 | Colorectum | AD | regulation of cellular component size | 142/3918 | 383/18723 | 1.74e-13 | 3.41e-11 | 142 |
| GO:1902903 | Colorectum | AD | regulation of supramolecular fiber organization | 139/3918 | 383/18723 | 2.01e-12 | 3.19e-10 | 139 |
| GO:0032970 | Colorectum | AD | regulation of actin filament-based process | 142/3918 | 397/18723 | 4.05e-12 | 5.90e-10 | 142 |
| GO:0110053 | Colorectum | AD | regulation of actin filament organization | 108/3918 | 278/18723 | 5.02e-12 | 6.98e-10 | 108 |
| GO:0008154 | Colorectum | AD | actin polymerization or depolymerization | 90/3918 | 218/18723 | 6.14e-12 | 8.23e-10 | 90 |
| GO:0032271 | Colorectum | AD | regulation of protein polymerization | 94/3918 | 233/18723 | 1.01e-11 | 1.29e-09 | 94 |
| GO:0030041 | Colorectum | AD | actin filament polymerization | 81/3918 | 191/18723 | 1.35e-11 | 1.69e-09 | 81 |
| GO:0051258 | Colorectum | AD | protein polymerization | 112/3918 | 297/18723 | 1.85e-11 | 2.27e-09 | 112 |
| GO:0043254 | Colorectum | AD | regulation of protein-containing complex assembly | 148/3918 | 428/18723 | 2.64e-11 | 3.18e-09 | 148 |
| GO:0008064 | Colorectum | AD | regulation of actin polymerization or depolymerization | 79/3918 | 188/18723 | 4.17e-11 | 4.74e-09 | 79 |
| GO:0030833 | Colorectum | AD | regulation of actin filament polymerization | 74/3918 | 172/18723 | 4.50e-11 | 5.03e-09 | 74 |
| GO:0030832 | Colorectum | AD | regulation of actin filament length | 79/3918 | 189/18723 | 5.71e-11 | 6.27e-09 | 79 |
| GO:1902905 | Colorectum | AD | positive regulation of supramolecular fiber organization | 85/3918 | 209/18723 | 5.95e-11 | 6.33e-09 | 85 |
| GO:0097193 | Colorectum | AD | intrinsic apoptotic signaling pathway | 108/3918 | 288/18723 | 6.25e-11 | 6.41e-09 | 108 |
| GO:0032956 | Colorectum | AD | regulation of actin cytoskeleton organization | 127/3918 | 358/18723 | 1.03e-10 | 1.04e-08 | 127 |
| GO:0051495 | Colorectum | AD | positive regulation of cytoskeleton organization | 89/3918 | 226/18723 | 1.61e-10 | 1.56e-08 | 89 |
| GO:0032273 | Colorectum | AD | positive regulation of protein polymerization | 62/3918 | 138/18723 | 1.94e-10 | 1.76e-08 | 62 |
| GO:0031334 | Colorectum | AD | positive regulation of protein-containing complex assembly | 91/3918 | 237/18723 | 4.78e-10 | 3.99e-08 | 91 |
| GO:0030838 | Colorectum | AD | positive regulation of actin filament polymerization | 48/3918 | 99/18723 | 9.21e-10 | 7.03e-08 | 48 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| JMY | SNV | Missense_Mutation | rs759301275 | c.1190N>A | p.Arg397Gln | p.R397Q | Q8N9B5 | protein_coding | tolerated(0.21) | benign(0.362) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| JMY | SNV | Missense_Mutation | novel | c.1647N>T | p.Glu549Asp | p.E549D | Q8N9B5 | protein_coding | deleterious(0.01) | possibly_damaging(0.689) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| JMY | SNV | Missense_Mutation | c.2259G>C | p.Gln753His | p.Q753H | Q8N9B5 | protein_coding | tolerated(0.14) | benign(0.003) | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| JMY | insertion | Nonsense_Mutation | novel | c.1854_1855insTGAAGTGGTATACTATGACACTTACGAAAGCATGG | p.Lys619Ter | p.K619* | Q8N9B5 | protein_coding | TCGA-A7-A0CG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| JMY | SNV | Missense_Mutation | novel | c.2390C>A | p.Ser797Tyr | p.S797Y | Q8N9B5 | protein_coding | tolerated(0.07) | possibly_damaging(0.66) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| JMY | SNV | Missense_Mutation | rs375111219 | c.133A>C | p.Thr45Pro | p.T45P | Q8N9B5 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| JMY | SNV | Missense_Mutation | rs531886847 | c.1565N>A | p.Arg522Gln | p.R522Q | Q8N9B5 | protein_coding | tolerated(0.36) | benign(0.009) | TCGA-IR-A3LB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| JMY | SNV | Missense_Mutation | c.2168N>T | p.Ser723Phe | p.S723F | Q8N9B5 | protein_coding | deleterious(0) | possibly_damaging(0.679) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| JMY | SNV | Missense_Mutation | rs375111219 | c.133N>C | p.Thr45Pro | p.T45P | Q8N9B5 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR |
| JMY | SNV | Missense_Mutation | rs375111219 | c.133N>C | p.Thr45Pro | p.T45P | Q8N9B5 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-VS-A9UD-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |